HRAS mutation

A3-1 📌3 family members: KRAS, NRAS & HRAS 📌KRAS mt: most common 📌NRAS: less common 📌HRAS: rare and unclear of impact In 5558 CRCs in cBioPortal, 40% KRAS, 5% NRAS, & 0.7% HRAS mutated. #CRCTrialsChat #CRCSM (@jonathanloree)

Are there any rare cancer trials for tipifarnib? Looking for someone with an HRAS G13V mutated angiosarcoma (@iskander)

👀 Check out what’s popular this week in #JCOPO: HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma 👉 https://t.co/DaT8SBve3S @LeXiuning @MDAndersonNews #hncsm (@JCOPO_ASCO)

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma @ttccgroup https://t.co/vj0R3669SI (@SantiCabezas1)

While HRAS mutations occur in a small subset of R/M HNSCC regardless of HPV status, clinical outcomes may be worse. This molecular event is actionable with tipifarnib/FTIs which has shown significant promise! 🧬🩺🧪 @kuraoncology https://t.co/Y1Q2WuIxs8 (@HeadNeckMD)

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma | JCO Precision Oncology https://t.co/d38w7ZRndz (@weldeiry)

HRAS mutation will be the first TKI-targetable oncogene in HNSCC. Our paper characterized this molecular subgroup in detail! HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma https://t.co/5yQPUi8lhg (@LeXiuning)

HRAS mutation can occur in both HPV-positive and HPV-negative #headandneckcancer (HNSCC) and a clinical benefit of FTase inhibition were observed in patients with mutant HRAS-HNSCC. @headandneckcan @drsania2289 @AncelJulienMD https://t.co/whBGxFfczO (@Dr_Ivanoncologo)

@kuraoncology @troyewilson Thank You for your attention. My father's suffering from cancer tongue now it's spreading in his lungs. In his NGS report, an HRAS gene missense mutation has been detected. He is under treatment by @DrVijayPatil11 at Tata Memorial Hospital Mumbai,india (@rsinghraghav17)

Representing my friend and ⭐️ fellow @AsaadTrabolsi with his great work on the tumor microenvironment of HRAS mutated #NSCLC at #ESMO22 @GlopesMd @Latinamd @HemOncFellows @SylvesterCancer @carisls (@ja_ocejo)

Inverted Urothelial Papilloma of the Bladder *⃣ Trabeculated architecture *⃣ Peripheral Palisading *⃣ Central Spindling Associated w/HRAS hotspot mutations: https://t.co/ESnou5Vvr4 #gupath (@rovingatuscap)

More to the RAS Story: Moving Beyond KRAS G12C Mutations in Lung Cancer talk by Colin R. Lindsay, #ASCO22 @OncoAlert Targeting HRAS mutant by attacking protein modifications Alternative approaches (@manjuggm)

Honored to have been given the opportunity to present our work in HRAS mutated lung cancer at #AACR2022 Shout out out to my mentors @Latinamd @GlopesMd and our awesome team @SamuelKareffMD @slowwalker919 @carisls @AACR (@AsaadTrabolsi)

.@marshposnermd on Leveraging Tipifarnib in HRAS-Mutant Head and Neck Cancer https://t.co/d3fpcaRPeu via @onclive @IcahnMountSinai (@TischCancer)

.@marshposnermd on Leveraging Tipifarnib in HRAS-Mutant Head and Neck Cancer https://t.co/d3fpcaRPeu via @onclive @MountSinaiNYC (@TischCancer)

RAF1 Amplification, HRAS/NRAS mutations collectively drive ~20% of #bladdercancer and confer sensitivity to MAPK-Directed Therapeutics @RaieBekele @mouwlab @DanaFarber-comment @aravi1 https://t.co/xPsOh4HCdz @practiceupdate (@sonpavde)

Inverted Urothelial Papilloma of the Bladder *⃣ Trabeculated architecture *⃣ Peripheral Palisading *⃣ Central Spindling Associated w/HRAS hotspot mutations: https://t.co/B8QiuSZSQJ #gupath (@rovingatuscap)

RAF1 amplification & HRAS/NRAS activating mutations drives ~20% #bladdercancer & confers preclinical sensitivity to MAPK targeted therapy- @mouwlab @rexirex @BrighamRadOnc @broadinstitute @DanaFarber_GU @AminNassarMD @OncoBellmunt @VanAllenLab https://t.co/BsDkYiisCh (@sonpavde)

WATCH NOW: @HeadNeckMD, of @DanaFarber, and @DrNabilSaba, of @EmoryUniversity give a brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma. #hncsm https://t.co/k2Cc2kHPpq (@OncLive)

I am a little late to seeing this paper from @AlanHoMDPhD . Important work demonstrating response rate to tipifarnib, a farnesyl transferase inhibitor, in HRAS mutant Head/Neck cancer. https://t.co/LT3ptRYLBB (@RielyMD)

Impressive response rate in high allelic frequency HRAS mutated head and neck cancer. Should this be new standard of care for these patients? https://t.co/lQ4RVRbnMk (@DrEzraCohen)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations https://t.co/HfaTopF32n (@VivekSubbiah)

Great to have a promising new treatment option for patients with mutant HRAS HNSCC ⁦@AlanHoMDPhD⁩ ⁦@DrNabilSaba⁩ ⁦@HeadNeckMD⁩ ⁦@KartikSehgal_MD⁩ https://t.co/Oh59OddSXk (@HNOPDFCI)

Good to see this data on the heals of @US_FDA breakthrough designation of tipifarnib in HRAS mutated #SCCHN ; hope to see an approval for another targeted agent in this disease, @ASCO_pubs, @AlanHoMDPhD, @sloan_kettering @HNOPDFCI,@WinshipAtEmory, https://t.co/MqCtArFmqT (@DrNabilSaba)

Let the fun begin @AkgulMd - complementing this #gupath cheatsheet on Urothelial Papilloma w/reference highlighting oncogenic KRAS/HRAS mutations in these lesions: https://t.co/B8QiuSZSQJ @h_alahmadie @drmehrarohit @evacomperat @GladellPaner @johncheville @drdonnahansel #bladder (@rovingatuscap)

#ICYMI: #In a previous episode of #OncLiveOnAir, @DrNabilSaba of @WinshipAtEmory discusses ongoing research with tipifarnib in HRAS-mutant head and neck squamous cell carcinoma. #hcsm https://t.co/zOOEmZNBDl (@OncLive)

Targeted therapy steps into the right direction in #Urothelialcarcinoma will be interesting to look at upper tract tumors with this drug as we reported HRAS mutations being enriched in renal pelvis tumors @EurUrolFocus @FoundationATCG https://t.co/0m7XD85rFf (@AndreaNecchi)

Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer - Hanna - 2020 - Cancer - Modest activity https://t.co/Z7KTVYjNjn (@Dr_R_Kurzrock)

Tipifarnib has modest activity in HRAS mutated salivary gland cancers which brings up the question of combination targeting. https://t.co/FAnMTEAMGI (@DrEzraCohen)

Congratulations to @HeadNeckMD, @AlanHoMDPhD, @DrEzraCohen and all of the co-authors for publication of their important paper “Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer” in @JournalCancer! (@kuraoncology)

Our work showing clinical activity for #tipifarnib in #HRAS mutated #salivary gland cancers 🔍💊🧬🩺 @kuraoncology @AlanHoMDPhD @DrEzraCohen https://t.co/0A0qTJrjMm (@HeadNeckMD)

Outcomes in HRAS mutated salivary gland cancers are disappointing relative to HNSCC. Unclear if comutation status or other variables prevented the type of responses we saw with HNSCC. #HNCSM #ASCO20 (@Jbauml)

At #ASCO20, Dr Ho presented some data on tipifarnib in HRAS mutant cancers. This is an important potential target in oral cavity cancer and salivary gland cancers. These cancers are generally highly refractory to systemic therapies, and we need better treatments! #HNCSM #ASCO20 (@Jbauml)